AUTISM SPECTRUM DISORDER (ASD)

1. DEFINITION AND HISTORICAL BACKGROUND

• Kaplan and Sadock's Synopsis of Psychiatry, p. 393

2. EPIDEMIOLOGY

• Prevalence: Currently about 1 in 54 children in the United States. The diagnostic rate has increased over the past two decades, partly due to broadened diagnostic criteria and increased awareness.
• Age of onset: Typically evident during the second year of life; some cases go undetected until middle childhood.
• Sex ratio: ASD is diagnosed 4 times more often in boys than girls. Girls, when diagnosed, are more likely to have accompanying intellectual disability. Girls without intellectual disability may be under-identified ("female protective effect" hypothesis).
• Age at diagnosis: Average of 3.1 years for autistic disorder, 3.9 years for PDD-NOS, and 7.2 years for Asperger disorder.

3. ETIOLOGY AND PATHOGENESIS

A. Genetic Factors

• ASD has significant heritable contribution; up to 15% of cases are associated with a known genetic mutation, but in most cases multiple genes are involved (polygenic).
• Concordance: ~36% in monozygotic twins vs. 0% in dizygotic twin pairs.
• Sibling recurrence rate: as high as 50% in families with two or more affected children.
• Researchers have identified susceptibility gene regions on chromosomes 2 and 7.
• The heterogeneity of expression suggests multiple patterns of genetic transmission.
• Genetic syndromes with ASD overlap: Fragile X syndrome, Tuberous sclerosis, Angelman syndrome.

B. Neurobiological Factors

• Brain volume: Structural and functional neuroimaging studies show increased total brain volume in children younger than 4 years - a possible biomarker.
• Serotonin: Elevated whole-blood serotonin (hyperserotonemia) is found in ~30% of children with ASD. This remains the most replicated biological finding.
• Neuroanatomy: Abnormalities in the amygdala, superior temporal sulcus, prefrontal cortex, and mirror neuron systems are implicated.
• Mitochondrial dysfunction: A 2024 systematic review and meta-analysis (PMID 38703861) confirmed mitochondrial biomarker abnormalities in ASD.

C. Immunological Factors

• Some children with ASD have abnormal immune profiles, and cytokine dysregulation has been documented.

D. Prenatal and Perinatal Factors

• Higher-than-expected incidence of prenatal and perinatal complications in infants who later develop ASD.
• Advanced parental age is a risk factor.

E. Neurocognitive Theories

• Mind-Blindness (Theory of Mind deficit): Children with ASD have difficulty understanding that other people have their own mental states, beliefs, and perspectives - they lack "theory of mind." (Baron-Cohen)
• Weak central coherence: Tendency to focus on details rather than the whole picture.
• Executive dysfunction: Difficulties with planning, cognitive flexibility, and inhibition.

4. CLINICAL FEATURES AND DSM-5 DIAGNOSTIC CRITERIA

Domain A: Persistent Deficits in Social Communication and Social Interaction

1. Deficits in social-emotional reciprocity - failure of back-and-forth conversation, reduced sharing of interests/emotions, failure to initiate or respond to social interactions.
2. Deficits in nonverbal communicative behaviors - poor eye contact, reduced facial expression and gestures, poor body language.
3. Deficits in developing and maintaining relationships - difficulties adjusting behavior to suit context, absence of interest in peers, failure to make friends.

Domain B: Restricted, Repetitive Patterns of Behavior, Interests, or Activities

1. Stereotyped or repetitive motor movements - hand-flapping, toe-walking, spinning objects, echolalia, idiosyncratic phrases.
2. Insistence on sameness - extreme distress at small changes, rigid adherence to routines, ritualistic patterns.
3. Highly restricted, fixated interests - abnormal in intensity or focus (e.g., intense preoccupation with specific objects or topics).
4. Hyper- or hyporeactivity to sensory input - unusual interest in sensory aspects of the environment, over- or under-sensitivity to pain, temperature, sounds, textures.

• Symptoms from BOTH domains (A and B)
• Symptoms present in the early developmental period (may not fully manifest until social demands exceed capacity)
• Symptoms cause clinically significant functional impairment
• Not better explained by intellectual disability alone

• With/without accompanying intellectual impairment
• With/without accompanying language impairment
• Associated with another neurodevelopmental/mental/behavioral disorder
• With catatonia

5. ASSOCIATED FEATURES

• Language: Although no longer a core criterion, language abnormalities are frequent. Echolalia, reversed pronouns, neologisms, and monotone speech may occur. In severe cases, language may never develop; in up to 25% of cases, some language develops and is then lost ("regression").
• Intellectual disability: ~1/3 of children with ASD have intellectual disability.
• Restricted play: Children often enjoy spinning, banging, water-watching; compulsive behaviors (lining up objects) are common.
• Anxiety: Extreme distress when routines are disrupted.
• Sensory differences: Apparent deafness to normal sounds but responses to low/soft sounds.
• Visual-spatial strength: Often more skilled in visual-spatial tasks than verbal reasoning tasks.
• Savant abilities: Exceptional skills in specific areas (music, math, memory) in a minority.

6. DIFFERENTIAL DIAGNOSIS

7. COURSE AND PROGNOSIS

• ASD is typically a lifelong disorder with highly variable severity.
• Best prognosis indicators: IQ above 70, average adaptive skills, and development of communicative language by ages 5-7.
• Early intensive behavioral intervention can produce profound positive change; in some cases, children may no longer meet criteria for ASD.
• Ritualistic and repetitive behaviors tend to improve less with age.
• A supportive home environment improves prognosis.

TREATMENT OF AUTISM SPECTRUM DISORDER

OVERVIEW

1. Target core behaviors to improve social interaction and communication
2. Reduce irritable, disruptive, and self-injurious behaviors
3. Expand academic, language, and adaptive skills
4. Support integration into schools and independent living
5. Psychoeducation and counseling for parents and caregivers

A. PSYCHOSOCIAL AND BEHAVIORAL INTERVENTIONS

1. Early Intensive Behavioral and Developmental Interventions

• Intensive, manualized, one-on-one intervention
• Uses techniques from Applied Behavior Analysis (ABA)
• Typically 20-40 hours/week
• Therapist and child practice specific social skills, language, and play skills
• Reinforcement and rewards provided for mastery
• Five RCTs of early intensive interventions (age 2-5 years) showed increases in language acquisition, social interactions, and educational achievement vs. controls

• Occurs in naturalistic settings (home, play environments)
• Combines ABA principles with developmental relationship-based approaches
• Emphasizes joint attention, social reciprocity, and play in a child-centered manner
• Evidence-based for ages 12-48 months

• Focuses on expanding joint attention and symbolic play
• Often used in classroom and community settings

2. Social Skills Training

• Group or individual programs teaching social conventions and prosocial behaviors
• Targets back-and-forth conversation, reading social cues, and friendship building
• Important for school-age children and adolescents

3. Speech and Language Therapy

• Addresses communication deficits (verbal and non-verbal)
• Augmentative and alternative communication (AAC) devices for non-verbal children
• Pragmatic language training (how language is used in social contexts)

4. Occupational Therapy

• Sensory integration therapy
• Fine motor skill development
• Activities of daily living (ADL) training

5. Educational Interventions

• Individualized Education Program (IEP) in school settings
• Structured teaching (TEACCH model - Treatment and Education of Autistic and related Communication Handicapped Children) - uses visual supports and structured environments
• Inclusive classrooms with support vs. specialized settings based on functional level

6. Parent Training and Participation

• Training parents as co-therapists
• Psychoeducation about ASD
• Parent-mediated interventions improve generalization of skills to the home environment
• Counseling and support groups for parents

7. Cognitive Behavioral Therapy (CBT)

• Adapted CBT for anxiety, depression, and OCD-like behaviors in higher-functioning individuals with ASD
• Particularly useful for adolescents and adults with average or above-average IQ

B. PHARMACOLOGICAL TREATMENT

1. Antipsychotics (for Irritability, Aggression, Self-injurious behavior)

• Both are atypical (second-generation) antipsychotics
• Monitor for weight gain, metabolic syndrome, EPS, prolactin elevation (risperidone), sedation

2. Selective Serotonin Reuptake Inhibitors (SSRIs) (for Repetitive Behaviors, Anxiety)

• Target repetitive behaviors, anxiety, and obsessive-compulsive features
• Fluoxetine, Fluvoxamine, Sertraline have been studied
• Fluvoxamine showed improvements in repetitive behaviors and social relatedness in adults in RCTs, but evidence in children is mixed
• Fluoxetine showed some improvement in repetitive behaviors in a placebo-controlled study
• Start at very low doses; children with ASD may be sensitive to activating effects (agitation, increased aggression)
• Clomipramine (TCA) has also been used but lacks strong RCT evidence

3. Stimulants and ADHD Medications (for Hyperactivity, Inattention)

• Methylphenidate - used for ADHD symptoms co-occurring with ASD; some benefit but response rates lower than in ADHD without ASD; higher rates of adverse effects (irritability, social withdrawal)
• Alpha-2 agonists (Guanfacine, Clonidine) - used for hyperactivity, impulsivity, aggression, and tic-like behaviors; better tolerability profile in some children with ASD
• Atomoxetine - some evidence for ADHD symptoms in ASD

4. Mood Stabilizers and Anticonvulsants (for Mood Instability, Epilepsy)

• Valproate - used for mood instability, seizures, and aggressive behaviors
• Lamotrigine - limited evidence for behavioral improvement in ASD
• ~25% of children with ASD have comorbid epilepsy, requiring standard anticonvulsant management

5. Melatonin (for Sleep Disturbances)

• Melatonin is one of the best-supported complementary/biological treatments for ASD
• Safe and efficacious: reduces sleep-onset latency in children with ASD
• Widely used and recommended

6. Naltrexone (Opioid Antagonist)

• Has been investigated for self-injurious behaviors based on the theory that blocking endogenous opioids would reduce autistic symptoms
• Results have generally been unsuccessful/equivocal

7. Bumetanide (Loop Diuretic - Investigational)

• Recent reports and studies suggest bumetanide may help treat ASD
• Mechanism: acts on NKCC1 (Na-K-Cl cotransporter), altering GABAergic function from excitatory to inhibitory in the developing brain
• Studies show improvements in communicative and cognitive abilities
• Cytokine measurements may help identify who will respond
• Still investigational; not approved for ASD

8. Venlafaxine (SNRI)

• Case reports suggest low-dose venlafaxine (18.75 mg/day) was efficacious in adolescents and young adults with ASD with self-injurious behavior and hyperactivity
• Evidence limited to case reports

C. COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM)

D. MULTIMODAL TREATMENT SUMMARY TABLE

RECENT EVIDENCE (2024-2025)

• A 2024 meta-analysis confirmed mitochondrial dysfunction biomarkers in ASD, opening new therapeutic avenues [PMID 38703861]
• A 2024 systematic review found physical exercise therapy produces significant improvements in ASD symptoms including social behavior, attention, and motor skills [PMID 38986177]
• A 2025 Lancet Psychiatry study on global ASD burden (GBD 2021) estimated substantial worldwide prevalence and health burden, reinforcing the need for accessible, evidence-based treatments [PMID 39709974]

KEY POINTS FOR EXAM

1. ASD has two core domains in DSM-5: social communication deficits + restricted/repetitive behaviors (language deviance is an associated, not core, feature)
2. 4:1 male-to-female ratio
3. Only FDA-approved drugs for ASD: Risperidone and Aripiprazole (for irritability)
4. Most evidence-based treatment for core symptoms: Early intensive behavioral interventions (ABA, ESDM)
5. Concordance in MZ twins ~36% (confirms strong genetic but not fully penetrant etiology)
6. Elevated whole-blood serotonin is the most replicated biological finding
7. Best prognosis: IQ >70, communicative language by age 5-7
8. Melatonin is the best-supported CAM for sleep
9. Secretin has been proven ineffective in RCTs
10. Treatment is multimodal - behavioral therapy is the cornerstone; medications target associated symptoms only

What's inside the document (8 sections, ~26KB):